Women’s Health11 min read·Published October 19, 2026

Libido Boosters for Women: What Helps, What Does Not, and When to Get Care

Low desire has many possible causes. Here is how to sort through lifestyle changes, prescription options, hormones, and common marketing claims.

The best libido booster for women depends on why desire changed. Stress, sleep loss, painful sex, vaginal dryness, mood, medications, health conditions, and menopause can all play a role.2 For some premenopausal women with distressing, persistent low desire, FDA-approved medicines may help; for others, treating the underlying cause is more useful.3 4

Not sure where to start? Take the 3-min clinical quiz.

See if you qualify →

What does “low libido” mean for women?

Low libido means lower sexual interest or desire than feels right for you. There is no universal “normal” level of desire. A lower level is not a disorder simply because it differs from a partner’s desire or from a past phase of life.

Clinicians focus on distress and context. In FSIAD, previously called hypoactive sexual desire disorder (HSDD), reduced interest or arousal lasts at least 6 months, causes meaningful distress, and is not better explained by a medical condition, a medication, severe relationship distress, or another mental health condition.1

Desire is also different from arousal, orgasm, and pain. Someone may want sex but have trouble becoming physically aroused. Another person may have desire but avoid sex because it hurts. These patterns can overlap, which is why a useful evaluation starts with the whole symptom picture rather than a single product.2

What can lower libido in women?

Female sexual desire is shaped by body, mind, relationships, and life stage. A change can be temporary, such as during a stressful month, or persist when several factors add up. A clinician may ask about symptoms, medicines, mood, relationship context, medical history, and pelvic symptoms before recommending treatment.2

  • Stress, sleep loss, depression, anxiety, trauma, and relationship strain can reduce interest in sex or make it harder to feel present during intimacy.2
  • Pain with sex, vulvodynia, pelvic floor dysfunction, and vaginal dryness can lead someone to avoid sex even when they still value intimacy.2
  • Some medicines, including certain antidepressants, can affect desire, arousal, or orgasm. Do not stop a prescribed medicine on your own; ask the prescriber about options.2
  • Diabetes, cardiovascular disease, neurologic conditions, and other chronic illnesses can affect sexual function through physical symptoms, mood, circulation, fatigue, or medication effects.2
  • Postpartum changes, perimenopause, menopause, and early menopause can affect desire directly or through sleep changes, hot flashes, dryness, and discomfort.2

For a closer look at the life-stage changes that can overlap with libido concerns, see our guide to perimenopause versus menopause symptoms.

How can women boost libido without medication?

Non-drug care is often the most sensible first step when there is an identifiable contributor such as pain, dryness, stress, or a medication effect. It does not mean the concern is “all in your head.” It means treatment should fit the cause.2

When intercourse is uncomfortable, addressing dryness, vulvovaginal symptoms, pelvic floor tension, or another pain source can be more important than trying to force desire. Menopause-related genitourinary symptoms can respond to lubricants, moisturizers, and clinician-guided treatments; the best choice depends on the symptoms and health history.7

  • Make room for sleep, recovery, and lower-pressure connection when stress and exhaustion are central.2
  • Use a water- or silicone-based lubricant during sex, and consider a vaginal moisturizer for ongoing dryness; a clinician can help with persistent symptoms.7
  • Consider individual sex therapy or couples therapy when communication, anxiety, trauma, or relationship patterns are a major part of the concern.2
  • Ask a clinician or pharmacist to review medications and health conditions that may affect sexual function.
  • Seek assessment for pain, bleeding, new pelvic symptoms, or persistent dryness rather than trying to work through discomfort.

Do female libido pills and enhancers work?

Prescription libido medicines can help a defined group of patients, but they are not instant or universal solutions. Trials of flibanserin and bremelanotide found statistically significant improvements in desire-related outcomes for selected premenopausal women with acquired, generalized HSDD; the average benefit was modest, and individual results vary.3 5

Over-the-counter products marketed as “female libido pills” are harder to judge. Supplements do not go through the FDA’s premarket drug approval process, and a label or online review cannot show whether a product is appropriate for your symptoms, medications, or health history.2 Be especially cautious with products that promise immediate, guaranteed, or hormone-like results without a clinical evaluation.

Is there a strong female Viagra?

There is no single “female Viagra” equivalent. Sildenafil (Viagra) was developed for erectile dysfunction and acts mainly on blood flow. Low desire in women often has different drivers, so sildenafil is not the standard treatment for low desire in women.2

Flibanserin (Addyi)

Addyi is the brand name for flibanserin, a non-hormonal serotonin 5-HT1A agonist and 5-HT2A antagonist. The FDA label approves it for acquired, generalized HSDD in premenopausal women; it is not for low desire caused by medical or psychiatric conditions, relationship problems, or medication effects.3 It is taken on a daily schedule rather than used on demand.

Its safety limits are important: flibanserin can cause dizziness, sleepiness, low blood pressure, and fainting. It has major CYP3A4 interaction concerns and is contraindicated with hepatic impairment.3 Those risks are why a medication and alcohol review matters before treatment.

Bremelanotide (Vyleesi)

Vyleesi is the brand name for bremelanotide, also called PT-141, a melanocortin receptor agonist. It is FDA-approved as an under-the-skin injection used before anticipated sexual activity for premenopausal women with acquired, generalized HSDD.4 In the RECONNECT trials, bremelanotide improved desire and distress measures versus placebo, though the size of improvement was modest on average.5

Nausea was common in clinical trials, and bremelanotide can temporarily raise blood pressure and lower heart rate. The FDA label lists uncontrolled hypertension and known cardiovascular disease as contraindications.4 It is not approved for all causes of low libido or for postmenopausal women.4

How do Addyi, Vyleesi, and PT-141 compare?

Addyi, Vyleesi, and PT-141 differ in mechanism, route, and regulatory status. The most important distinction is that FDA-approved Vyleesi is an under-the-skin injection, while a compounded PT-141 nasal spray is a different formulation with different available evidence.4

OptionWhat it isRoute and timingWho it is approved forKey safety issues
Addyi (flibanserin)Serotonergic medicationOral tablet taken dailyCertain premenopausal women with acquired, generalized HSDDSleepiness, dizziness, hypotension, syncope, liver-related contraindication, and CYP3A4 interactions.3
Vyleesi (bremelanotide)Melanocortin receptor agonistUnder-the-skin injection before anticipated sexual activityCertain premenopausal women with acquired, generalized HSDDNausea, temporary blood-pressure increase, and cardiovascular contraindications.4
Compounded PT-141 nasal sprayCompounded formulation containing PT-141/bremelanotideNasal spray; provider-guided useNot FDA-approved for any indication.4Evidence from FDA-approved Vyleesi injection does not establish outcomes for a compounded nasal formulation.4

A clinician should match treatment to the symptom pattern and safety profile. For example, a person with painful sex or vaginal dryness may need that concern addressed first; someone with antidepressant-associated sexual dysfunction may need a medication review; and a person with possible HSDD may need a fuller assessment of distress, duration, and contributing factors.1 2

3-min quiz

Explore clinician-reviewed sexual wellness care

Chia offers PT-141 nasal spray and the Spark protocol after an online clinical review. A prescription requires a medical evaluation and is not guaranteed. Medications are compounded by US state-licensed 503A pharmacies, shipped to your door, and compounded drugs are not FDA-approved.4

How does female libido care work at Chia?

At Chia, we offer compounded PT-141 nasal spray and Spark, which includes compounded PT-141 nasal spray, for patients whose clinician determines treatment is appropriate. PT-141 is another name for bremelanotide, but our compounded nasal spray is not FDA-approved and is not the same as FDA-approved Vyleesi injection.4

Care begins with a short online health questionnaire. A licensed US provider reviews your history and prescribes only when clinically appropriate. If prescribed, medication is compounded in the United States by a state-licensed 503A pharmacy and shipped to your door; dosing is provider-guided, and you can message your care team through the patient portal.

Low desire during menopause may be connected to dryness, pain, sleep disruption, or other symptoms that call for a different conversation.2 7 Chia also offers estradiol in cream, injection, and transdermal patch forms, as well as progesterone in cream and injection forms, when a provider finds hormone care clinically appropriate. These treatments are not general libido boosters, and they are not right for every person. You can also read our overview of low sex drive treatment and our detailed guide to PT-141.

If you use an AI assistant to organize care, Chia can also be reached through DoctorMCP at mcp.chia.health for clinician-reviewed access where appropriate. An online request never replaces the provider evaluation, and a prescription is never guaranteed.

Which option fits which person?

The right next step depends on what is driving the change, not on which product has the strongest marketing. This table can help you prepare for a clinician conversation.

What is going onSensible next stepWhy it matters
Pain, burning, dryness, or bleeding with sexPelvic and gynecologic evaluation; discuss lubricants, moisturizers, and menopause-related care when relevantPain can reduce desire and may need treatment before libido-specific medicine.2 7
A new problem after starting an antidepressant or another medicineMedication review with the prescribing clinicianA medicine may contribute, but it should not be stopped abruptly.2
Persistent, distressing low desire without another clear cause in a premenopausal womanAsk about assessment for acquired, generalized HSDD and the risks and limits of FDA-approved optionsFlibanserin and bremelanotide have narrow labeled populations and meaningful safety considerations.3 4
Hot flashes, vaginal symptoms, sleep disruption, or cycle changes around midlifeDiscuss menopause or perimenopause evaluationLife-stage symptoms can affect comfort, sleep, and sexual well-being.7
Stress, anxiety, relationship strain, or trauma is centralConsider individual therapy, sex therapy, or couples therapySexual desire is influenced by emotional and relationship context.2

When should a woman see a clinician about low libido?

See a clinician when low desire lasts 6 months or longer and causes distress, or sooner if the change is sudden or accompanied by other symptoms. An evaluation can help separate low desire from arousal, orgasm, pain, medication, mood, or hormone concerns.1

  • Pain during sex, bleeding after sex, pelvic pain, sores, or persistent burning or itching.
  • A sudden loss of desire after a new medication, illness, surgery, pregnancy, or major life change.
  • Depression, anxiety, trauma symptoms, or safety concerns in a relationship.
  • Hot flashes, vaginal dryness, urinary symptoms, or other menopause-related concerns.
  • Chest pain, uncontrolled blood pressure, cardiovascular disease, liver disease, or medicines that could interact with a prescription libido treatment.3 4

A clinician may ask about symptom timing, sexual comfort, mood, relationship context, medications, menstrual or menopause symptoms, and health history. Testing is not always needed; it depends on the history and exam findings.2

What questions should you ask before trying a libido booster?

A clear cause is more useful than a quick fix. Bring these questions to a visit so treatment can fit your health and goals.

  1. 1What may be contributing to my lower desire: pain, dryness, sleep, stress, mood, medication, hormones, or another health condition?
  2. 2Do my symptoms fit a low-desire condition such as HSDD, or do they point to another sexual-health concern?
  3. 3What benefits are realistic, and how long might it take to know whether a treatment is helping?
  4. 4What side effects, contraindications, alcohol warnings, or medication interactions apply to me?
  5. 5Is this option FDA-approved, compounded, or an over-the-counter supplement, and what evidence exists for this exact formulation?

FAQ: libido boosters for women

3-min quiz

Talk with a clinician about low desire

If low libido is persistent or distressing, start with an online health questionnaire and a licensed provider review. You can learn more about PT-141 nasal spray before your visit. A prescription is not guaranteed, and compounded medications are not FDA-approved.4


References

  1. 1.Katz M, DeRogatis LR, Ackerman R, et al. Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women. P&T. 2016.
  2. 2.Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. A practical guide to female sexual dysfunction: an evidence-based review for physicians. Canadian Urological Association Journal. 2018.
  3. 3.U.S. Food and Drug Administration. Addyi (flibanserin) prescribing information. 2025.
  4. 4.U.S. Food and Drug Administration. Vyleesi (bremelanotide injection) prescribing information. 2019.
  5. 5.Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019.
  6. 6.Kumar M, Nizamie SH, Jahan M. Flibanserin: A controversial drug for female hypoactive sexual desire disorder. Industrial Psychiatry Journal. 2018.
  7. 7.The North American Menopause Society. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020.
  8. 8.Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Journal of Sexual Medicine. 2021.

About this article

Chia Health Editorial Team — Evidence-reviewed health education

This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.

AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.

Get a personalized plan

Find what fits your body and your goals.

Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.

Take the 3-min quiz

Keep reading

Back to all guides